Objective Iran has the highest rate of opiate use worldwide. However, most opiate users are not screened for hepatitis virus infections. This study aimed to provide accurate, detailed data on the size of the opiate user population at risk of developing these infections. Method This seroprevalence study was conducted in the city of Shiraz, southern Iran. All participants were screened for HBV, HCV and HIV infection. The data were analyzed with SPSS. Result Among 569 participants, 233 (40.9%) were injection drug users (IDU), 369 (64.8%) were heterosexual, 84 (14.7%) were bisexual and 15 (2.6%) were homosexual. One hundred nine (19.1%) were HCV antibody-positive, 18 (3.1%) were HBS antigen-positive, 72 (12.6%) were HBc antibody-positive and 23 (4%) were HIV-positive. Among IDU compared to non-IDU, positivity rates for HBS antigen (5.5 vs 1.4%), HBc antibody (22.7 vs 5.6%), HCV antibody (40.3 vs 4.4%) and HIV (7.7 vs 1.4%) were higher (P < 0.05). Most patients with HBV (80.7%) and HCV infection (83.4%) were HIV-negative. In the cumulative analysis, only history of imprisonment was a statistically significant determinant of infection by HCV or HBV in opiate users. Conclusion The current policy of screening only HIV-positive drug users for HBV and HCV in Iran misses most cases of HBV and HCV infection. We therefore recommend urgent revision of the nationwide protocol by the Ministry of Health in Iran to implement routine screening of all opiate users and especially IDU for these viruses, regardless of their HIV status.
References
[1]
United Nations Office On Drugs and Crime. PREFACE. World Drug Report 2012. Available: . http://www.unodc.org/unodc/en/data-and-a？nalysis/WDR-2012.html. Accessed 22 April 2013.
[2]
United Nations Office On Drugs and Crime. Maps. Prevalence of drug use among the general population. World Drug Report 2012. Available: . http://www.unodc.org/unodc/en/data-and-a？nalysis/WDR-2012.html. Accessed 22 April 2013.
[3]
United Nations Office on Drugs and Crime. The opium/heroin market in. World Drug Report 2011. Available: . http://www.unodc.org/unodc/en/data-and-a？nalysis/WDR-2011.html. Accessed 22 April 2013.
[4]
Khademi H, Malekzadeh R, Pourshams A, Jafari E, Salahi R et al. (2012) Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50？000 adults in Iran. BMJ 344: e2502. doi:10.1136/bmj.e2502. PubMed: 22511302.
[5]
United Nations Office On Drugs and Crime. Drug-related mortality with ranking of drugs as primary cause of death (2010 or latest year available). World Drug Report 2012. Available: . http://www.unodc.org/unodc/secured/wdr/D？rug-related_Mortality_2012.pdf. Accessed 22 April 2013.
[6]
Honarvar B, Lankarani KB, Odoomi N, Roudgari A, Moghadami M, et al. (2013). Pulmonary and latent tuberculosis screening in opiate drug users: an essential and neglected approach for harm-reduction facilities. Journal of Addiction Medicine. PMID: 23666320.
[7]
United Nations Office On Drugs and Crime. Drug use – nature and typology. World Drug Report 2010. Available: . http://www.unodc.org/unodc/en/data-and-a？nalysis/WDR-2010.html. Accessed 22 April 2013.
[8]
Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D et al. (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378(9791): 571-583. doi:10.1016/S0140-6736(11)61097-0. PubMed: 21802134.
[9]
United Nations Office On Drugs and Crime. Expert perception of trend changes in the use of opioids 2010 (or latest year available back to 2006). World Drug Report 2012. Available: . http://www.unodc.org/unodc/secured/wdr/W？DR12_Trends_maps.pdf. Accessed 22 April 2013.
[10]
United Nations Office On Drugs and Crime. Transnational drug market analysis: The opium/heroin market. World Drug Report 2010. Available: . http://www.unodc.org/unodc/en/data-and-a？nalysis/WDR-2010.html. Accessed 22 April 2013.
[11]
World Health Organization. Hepatitis C - Fact sheet No. 164. Available: . http://www.who.int/mediacentre/factsheet？s/fs164/en/. Accessed 22 April 2013.
[12]
Rahimi-Movaghar A, Razaghi EM, Sahimi-Izadian E, Amin-Esmaeili M, Rahimi-Movaghar A et al. (2010) HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis 14(1): e28-e33. doi:10.1016/j.ijid.2009.03.002. PubMed: 19464218.
[13]
Keramat F, Eini P, Majzoobi MM, Keramat F, Eini P et al. (2011) Seroprevalence of HIV, HBV and HCV in Persons Referred to Hamadan Behavioral Counseling Center, West of Iran. Iran Red Crescent Med J 13(1): 42-46. PubMed: 22946017.
[14]
World Health Organization. Hepatitis BFact sheet No. 204. Available: . http://www.who.int/mediacentre/factsheet？s/fs204/en/. Accessed 22 April 2013.
[15]
Davarpanah MA, Darvishi M, Mehrabani D (2007) The Prevalence of HBS antigenemia in patients with HIV infection in Shiraz, southern Iran. Iranian Red Crescent Medical Journal 9(4): 224-225.
[16]
Zhou YH, Yao ZH, Liu FL, Li H, Jiang L, et al. (2012) High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLOS ONE 7(8): e42937. doi:10.1371/journal.pone.0042937. PubMed: 22916185.
[17]
Sofian M, Aghakhani A, Banifazl M, Azadmanesh K, Farazi AA, et al. (2012) Viral hepatitis and HIV infection among injection drug users in a central Iranian City. J Addict Med 6(4): 292-296. doi:10.1097/ADM.0b013e3182659928. PubMed: 22895463.
[18]
Davarpanah MA, Saberi-Firouzi M, Lankarani KB, Mehrabani D, Behzad-Behbahani A et al. (2009) Hepatitis C Virus Genotype Distribution in Shiraz, Southern Iran. Hepatitis Monthly 9(2): 122-127.
[19]
Mehrabani D, Davarpanah MA, Rafiee G, Allahyari S (2008) High-risk behaviors in HIV positive individuals in Shiraz. Iranian. Clinical Infectious Diseases 3(4): 209-213.
[20]
Zamani S, Radfar R, Nematollahi P, Fadaie R, Meshkati M, et al. (2010) Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 21(6): 493-500. doi:10.1016/j.drugpo.2010.04.006. PubMed: 20483578.
[21]
Winter RJ, Dietze PM, Gouillou M, Hellard ME, Robinson P et al. (2013) Hepatitis B virus exposure and vaccination in a cohort of people who inject drugs: What has been the impact of targeted free vaccination? J Gastroenterol Hepatol 28(2): 314-322. doi:10.1111/jgh.12063. PubMed: 23190264.
[22]
Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H et al. (2011) Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon 11(1): 19-22. PubMed: 22087111.
[23]
World Health Organization. Viral Hepatitis. Sixty-third World Health Assembly. Available: . http://apps.who.int/iris/handle/10665/30？92. Accessed 22 April 2013.
